Core Viewpoint - The controlling shareholder and chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025 [1] Group 1: Shareholding Increase Plan - Xiong Jun intends to purchase both A-shares and H-shares of Junshi Biosciences, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase plan is still ongoing, and Xiong Jun will continue to buy shares as per the outlined plan during the implementation period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年11月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 重要内容提示： 上海君实生物医药科技股 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-065 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 上海君实生物医药科技股份有限公司（以下简称"公司"）控股股东、 实际控制人之一兼董事长熊俊先生拟自 2025 年 4 月 12 日起 12 个月内，通过上 海证券交易所交易系统与香港联合交易所有限公司允许的方式（包括但不限于集 中竞价和大宗交易等方式）增持公司 A 股股份及 H 股股份，合计增持金额不低 于人民币 1 亿元，其中 A 股增持金额不低于人民币 5,000 万元。 截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式 累计增持公司 A 股股份 100,000 股，约占公司总股本的 0.01%，累计成交总额为 人民币 383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 本次增持计划可能存在因资本市场 ...

格隆汇11月10日丨君实生物(688180.SH)公布，截至本公告披露日，实际控制人之一兼董事长熊俊先生 通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占公司总股本的0.01%，累 计成交总额为人民币383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增持计划，在 增持计划实施期间内择机增持公司股份。 ...

Core Points - The actual controller and chairman of Junshi Biosciences, Mr. Xiong Jun, has cumulatively increased his holdings in the company's A-shares by 100,000 shares, representing approximately 0.01% of the total share capital [1] - The total transaction amount for this increase in holdings is RMB 3.8384 million [1] - The share buyback plan is not yet completed, and Mr. Xiong will continue to increase his holdings in the company during the implementation period of the buyback plan [1]

Market Overview - The metal new materials sector experienced a decline of 0.98% on November 10, with Yunlu Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Stock Performance - Jiangnan New Materials (603124) saw a significant increase of 8.15%, closing at 89.66 with a trading volume of 64,900 shares and a transaction value of 575 million [1] - Sry New Materials (688102) rose by 5.15%, closing at 20.40 with a trading volume of 300,800 shares and a transaction value of 629 million [1] - In contrast, Yunlu Co., Ltd. (688180) fell by 8.08%, closing at 115.25 with a trading volume of 17,500 shares and a transaction value of 207 million [2] Capital Flow - The metal new materials sector saw a net outflow of 844 million from institutional investors, while retail investors contributed a net inflow of 743 million [2] - The overall capital flow indicates that retail investors are actively buying into the sector despite the institutional sell-off [2] Individual Stock Capital Flow - Jiangnan New Materials had a net inflow of 68.28 million from institutional investors, while retail investors had a net outflow of 55.55 million [3] - Longmag Technology (300835) experienced a net inflow of 12.87 million from institutional investors, with retail investors also showing a net outflow of 19.28 million [3] - The data suggests a mixed sentiment among different investor types, with institutional investors pulling back while retail investors remain engaged [3]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has gained 1.2% with a trading volume of 351 million yuan and a total fund size of 2.079 billion yuan as of November 10 [1] - Key performing stocks within the ETF include InnoCare Pharma-B, Bionet, and Ascletis Pharma, with respective gains of 5.4%, 4.43%, and 4.37% [1] - Conversely, stocks such as Kangzhe Pharmaceutical, MIRXES-B, and Innovent Biologics showed weaker performance, with declines of 1.28%, 0.94%, and 0.65% respectively [1] Group 2 - The innovative drug sector is identified as the largest investment opportunity in the pharmaceutical sector for 2025, with a focus on dual/multi-target drugs, chronic disease medications addressing unmet clinical needs, and ADCs [2] - There is a noted improvement in domestic and international innovative drug financing data, with an upward trend in CXO industry orders, indicating a potential recovery in valuations and performance [2] - The medical device sector is experiencing accelerated approvals for innovative products, such as the approval of the chest and abdominal aortic stent system by Xianjian Technology, which is expected to enhance long-term profit margins [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF and its linked funds passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with the top ten weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Viewpoint - The A-share market is experiencing a rebound with strong performance in sectors like consumer goods, food and beverage, and oil, while sectors such as communication and electronics are under pressure. The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has seen a significant inflow of funds, accumulating over 190 million yuan in nine consecutive days, with a total scale exceeding 500 million yuan [1][3]. Group 1: Market Performance - The A-share market is showing a mixed trend, with certain sectors like consumer goods and food and beverage performing strongly, while others like communication and electronics are facing challenges [1]. - The "20CM New Species" Sci-Tech Innovation Drug ETF Huatai (589120) has risen over 1% amid this market fluctuation, indicating investor interest in innovative drug sectors [1]. Group 2: Fund Inflows and Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) has attracted over 190 million yuan in funds over the past nine days, reflecting strong investor confidence in the innovative drug sector [1]. - The ETF's latest scale has surpassed 500 million yuan, showcasing its growing popularity among investors [1]. Group 3: Company-Specific Developments - BeiGene reported a 41% year-on-year increase in third-quarter revenue, reaching 1.41 billion USD, primarily driven by strong sales of its drug, Zebrutinib [3]. - Several component stocks of the ETF, such as Teva Biopharma and Zai Lab, have shown positive performance, with Teva Biopharma rising over 4% [3][4]. Group 4: Policy and Market Dynamics - The National Medical Insurance Administration is conducting negotiations for the medical insurance drug catalog, with 120 companies participating, indicating a significant policy shift aimed at enhancing drug accessibility [5][6]. - The introduction of a dual catalog negotiation system allows pharmaceutical companies more strategic options, potentially leading to better market access for innovative drugs [6][7]. Group 5: Future Outlook - The innovative drug sector is expected to continue thriving, supported by favorable policies and increasing international collaboration, with projections indicating substantial market growth by 2030 [8]. - The focus on innovative drugs, particularly in the context of the upcoming medical insurance negotiations, is likely to enhance the market landscape for these products [8].

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating high levels of financing and short selling [1][2] Group 2 - On November 7, Junshi Biosciences' stock fell by 1.92%, with a trading volume of 292 million yuan. The financing buy-in amount was 2.023 million yuan, while the financing repayment was 26.51 million yuan, resulting in a net financing buy of -627.79 thousand yuan [1] - As of November 7, the total financing and securities lending balance for Junshi Biosciences was 1.402 billion yuan, with the financing balance at 1.389 billion yuan, accounting for 4.80% of the circulating market value, which is above the 90th percentile level over the past year [1] - On the same day, Junshi Biosciences repaid 1,490 shares in securities lending and sold 2,000 shares, with a selling amount of 75.6 thousand yuan. The remaining securities lending volume was 32.85 thousand shares, with a balance of 12.4132 million yuan, also above the 90th percentile level over the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs. The main revenue sources are 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [2] - As of September 30, 2025, the top ten circulating shareholders included E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with both funds reducing their holdings compared to the previous period [2]

Group 1 - The core viewpoint of the news highlights the performance of Chinese innovative pharmaceutical companies, with notable gains from Junshi Bioscience, CanSino Biologics, and Kintor Pharmaceutical, while companies like 3SBio, Lepu Biopharma-B, and BeiGene experienced declines [1] - The Hong Kong innovative pharmaceutical sector is gaining global capital attention as a "value highland," with multiple Chinese innovative drug companies advancing candidate drugs into clinical stages using AI platforms by November 3, 2025 [1] - Recent sentiment in the innovative drug sector has declined, but the sector's sustainability remains intact, with a trend towards "innovation + internationalization" [1] Group 2 - The innovative drug industry is transitioning from a quantity-driven logic to a quality-driven logic, entering a phase where product quality is paramount [1] - The 2025 outlook suggests focusing on differentiated domestic and international pipelines, with an emphasis on products and companies that can deliver profits [1] - There is an expectation of continued recovery in overseas financing and a potential bottoming out of domestic financing, indicating an upcoming wave of innovation [1] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked funds passively track the Hang Seng Stock Connect Innovative Drug Select Index, with top-weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [2] - The ETF has shown resilience, with a recent inflow of 130 million yuan over five days, indicating continued interest from investors [4]